No profile data available.
Pharvaris N.v. (PHVS) is a healthcare company in the immunodeficiency treatment drugs industry, based in Zug, Switzerland, with about 148 full-time employees.
It reported revenue of 0 EUR for fiscal year 2025, and net income of -175.70 million EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 0 EUR. Its market capitalization was $2.18 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Pharvaris reported 0 EUR in revenue for fiscal year 2025. In Q2 2026 revenue was 0 EUR.
$2.18 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (immunodeficiency treatment drugs) include BioCryst Pharmaceuticals, Inc. (BCRX), Pharming Group N.v. (PHAR), X4 Pharmaceuticals, Inc. (XFOR), AIM ImmunoTech Inc. (AIM).